Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Other Events

ITEM8.01

On March 31, 2017, Kadmon Holdings, Inc. (the Company) submitted
an Abbreviated New Drug Application to the U.S. Food and Drug
Administration (FDA)for KD034,the Companys trientine
hydrochloride formulation.This is the second application
submitted to the FDA by any company for a generic trientine
hydrochloride product for the treatment of Wilsons disease in
patients who are intolerant of penicillamine.Wilsons disease is a
genetic liver disease characterized by an inability to excrete
copper, causing severe hepatic, neurologic, psychiatric and
ophthalmic abnormalities. The full text of the press release is
attached to this Current Report on Form 8-K as Exhibit 99.1.

(d) Exhibits.

About Kadmon Holdings, Inc. (NYSE:KDMN)

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

Kadmon Holdings, Inc. (NYSE:KDMN) Recent Trading Information

Kadmon Holdings, Inc. (NYSE:KDMN) closed its last trading session down -0.07 at 3.47 with 167,618 shares trading hands.